基于不同人口学特征的急性加重期慢性阻塞性肺疾病患者临床特征及预后危险因素分析

注册号:

Registration number:

ChiCTR2600122360 

最近更新日期:

Date of Last Refreshed on:

2026-04-13 11:24:56 

注册时间:

Date of Registration:

2026-04-13 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于不同人口学特征的急性加重期慢性阻塞性肺疾病患者临床特征及预后危险因素分析

Public title:

Analysis of Clinical Characteristics and Prognostic Risk Factors in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Patients Based on Different Demographic Characteristics

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于不同人口学特征的急性加重期慢性阻塞性肺疾病患者临床特征及预后危险因素分析

Scientific title:

Analysis of Clinical Characteristics and Prognostic Risk Factors in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Patients Based on Different Demographic Characteristics

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王宇 

研究负责人:

王宇 

Applicant:

Wang Yu 

Study leader:

Wang Yu 

申请注册联系人电话:

Applicant telephone:

+86 138 8978 7905

研究负责人电话:

Study leader's
telephone:

+86 412 593 0265

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

970076472@qq.com

研究负责人电子邮件:

Study leader's E-mail:

970076472@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

辽宁省鞍山市铁东区中心医院

研究负责人通讯地址:

中华南路77号

Applicant address:

Liaoning Anshan City Tiedong District Central Hospital

Study leader's address:

No. 77 South Zhonghua Road, Tiedong District, Anshan, Liaoning province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

辽宁省鞍山市铁东区中心医院

Applicant's institution:

Liaoning Anshan City Tiedong District Central Hospital

研究负责人所在单位:

鞍山市中心医院

Affiliation of the Leader:

Anshan Central Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

鞍山中心伦审[2025]-013-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

鞍山市中心医院伦理委员会

Name of the ethic committee:

Ethics Committee of Anshan Central Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-11-15 00:00:00

伦理委员会联系人:

赵立伟

Contact Name of the ethic committee:

Zhao LiWei

伦理委员会联系地址:

中华南路77号

Contact Address of the ethic committee:

No. 77 South Zhonghua Road, Tiedong District, Anshan, Liaoning province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 412 555 5207

伦理委员会联系人邮箱:

Contact email of the ethic committee:

3243632727@qq.com

研究实施负责(组长)单位:

鞍山市中心医院

Primary sponsor:

Anshan Central Hospital

研究实施负责(组长)单位地址:

中华南路77号

Primary sponsor's address:

No. 77 South Zhonghua Road, Tiedong District, Anshan, Liaoning province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

辽宁省

市(区县):

Country:

China

Province:

Liaoning

City:

单位(医院):

鞍山市中心医院

具体地址:

中华南路77号

Institution
hospital:

Anshan Central Hospital

Address:

No. 77 South Zhonghua Road, Tiedong District, Anshan, Liaoning province

经费或物资来源:

鞍山市中心医院

Source(s) of funding:

Anshan Central Hospital

研究疾病:

慢性阻塞性肺疾病  

Target disease:

Chronic Obstructive Pulmonary Disease

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

通过前瞻性队列研究,动态收集鞍山地区不同人口学特征(如性别、年龄)AECOPD患者的基线临床症状、并发症、实验室检查、肺功能指标及随访治疗结局的差异;分析主要人口学特征与上述临床特征的关联,为针对性干预提供即时数据支持,重点探讨关键人口学特征人群与预后的关联;为制定个体化治疗策略提供科学依据,改善患者预后。  

Objectives of Study:

A prospective cohort study will be conducted to dynamically collect differences in baseline clinical symptoms, complications, laboratory tests, pulmonary function indicators, and follow-up treatment outcomes among patients with AECOPD in Anshan area with different demographic characteristics (such as gender and age); analyze the correlation between key demographic characteristics and the above-mentioned clinical features to provide real-time data support for targeted interventions; focus on exploring the correlation between key demographic groups and prognosis; and provide a scientific basis for formulating individualized treatment strategies to improve patient outcomes.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. 年龄 <18 岁; 2. 住院时间 < 48 小时; 3. 孕妇或哺乳期女性; 4. 合并支气管扩张、肺癌等其他慢性呼吸系统疾病; 5. 认知障碍或无法配合随访者。

Exclusion criteria:

1.Age < 18 years;
2.Length of hospital stay < 48 hours;
3.Pregnant or lactating females;
4.Concomitant chronic respiratory diseases such as bronchiectasis and lung cancer;
5.Individuals with cognitive impairment or inability to comply with follow-up.

研究实施时间:

Study execute time:

From 2025-01-01 00:00:00 To 2027-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-04-13 00:00:00 To 2027-12-31 00:00:00

干预措施:

Interventions:

组别:

观察组

样本量:

70

Group:

Observation group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

辽宁省 

市(区县):

 

Country:

China

Province:

Liaoning

City:

单位(医院):

鞍山市中心医院 

单位级别:

三级甲等 

Institution
hospital:

Anshan Central Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

一年内COPD急性加重次数

指标类型:

主要指标

Outcome:

Number of COPD Exacerbations Within One Year

Type:

Primary indicator

测量时间点:

出院后

测量方法:

一年内COPD急性加重次数。

Measure time point of outcome:

After Discharge

Measure method:

Number of COPD Exacerbations Within One Year

指标中文名:

因 COPD 短期再入院率

指标类型:

次要指标

Outcome:

Short-term readmission rate due to COPD

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

1 年内死亡率

指标类型:

次要指标

Outcome:

1-year mortality rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

no

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

no

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-04-13 11:24:50